Immuno-oncology
From the Journals
Pembrolizumab advances in relapsed/refractory classic Hodgkin lymphoma
The overall response rate was 69% with immune checkpoint inhibitor.
News
Durvalumab approved for advanced urothelial carcinoma
The Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor durvalumab for patients with locally advanced or...
Conference Coverage
Nivolumab boosts 5-year survival in advanced NSCLC
Treatment with nivolumab resulted in a 5-year overall survival rate that is much higher than what is reported for this patient population...
Conference Coverage
Get ready for cancer immunotherapy-induced rheumatic diseases
SNOWMASS, COLO. – New therapies and clinical trials will result in increased rheumatologic immune-related adverse events.
Conference Coverage
VIDEO: It’s too early to give up on immunotherapy for breast cancer
MIAMI BEACH – Breast cancer is less immunogenic that melanoma, bladder cancer, lung cancer, and other malignancies that have responded well to...
From the Journals
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
For the first time, new-onset connective tissue disease has been reported in patients who were treated with anti-PD1/PDL-1 agents, according to...
Conference Coverage
Soluble PD-L1 correlates with melanoma outcomes
ORLANDO – Can soluble PD-L1 be used to predict malignant melanoma outcomes?
Conference Coverage
Vaccine + chemo induce robust T-cell responses in late-stage cervical cancer
ORLANDO – HPV patients’ immune response increases with combined vaccine/chemo approach.
Conference Coverage
Genomic differences seen in mRCC during first- and second-line therapy
ORLANDO – Genomic differences in mRCC patients underscore potential mechanisms of resistance.
From the Journals
Nivolumab + ipilimumab induced fulminant, fatal myocarditis
Two patients taking the immune checkpoint inhibitors nivolumab and ipilimumab for metastatic melanoma developed fulminant, fatal myocarditis.
Conference Coverage
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
Pembrolizumab was superior to chemotherapy in stage IV NSCLC with PD-L1 expression of 50% or more.